Renasight Clinician | Natera

Product Spotlight

Affordable and accessible genetic testing on 382 genes associated with kidney disease

Testing Simplified

Learn more about Renasight kidney gene panel for your clinic


Introducing a new tool for the management of kidney disease

Designed for patients who have been diagnosed with or who have a family history of chronic kidney disease (CKD), electrolyte disorders, or nephrolithiasis

 

  • Leverages next-generation sequencing and other methodologies on more than 380 genes associated with kidney disease.

  • Identifies autosomal dominant, autosomal recessive, and X-linked disorders.

  • Reports out pathogenic and likely pathogenic variants that were hand selected by genetic experts to provide actionable information.


Interested in learning more about Renasight?

Learn more


Built on evidence


A recent New England Journal of Medicine publication assessing the incidence of genetic disease in a CKD population found ~1 in 10 patients have a genetic diagnosis.1

 


 

Pinpoint and plan


In 89% of patients of CKD, a genetic diagnosis had implications for clinical management.1


Renasight provides valuable information for patient management

 

 

Gain prognostic insight

Identify an etiology for patients with unknown cause of their CKD

Prescribe targeted therapies


Refer patients earlier for extra-renal features

Test family members and offer genetic counseling

Enroll patients in clinical trials


Changing care with Renasight

Contact us to discover how Renasight can be incorporated into your clinical practice

Learn more


Support every step of the way

Renasight is designed for seamless integration into your clinical practice

Learn more about NateraCore services.

 

 


Natera is committed to patient affordability

We welcome all insurance plans and provide affordable testing through a variety of of payment methods. Natera offers discounted self-pay pricing and financial assistance through our compassionate care program.

The Natera team is here to help you with any billing or reimbursement questions at
+1 650.425.4005.


Request more information about Renasight

 

References

  1. Groopman EE, Marasa M, Cameron-Christie S et al. Diagnostic utility of exome sequencing for kidney disease. NEJM. 2018;doi:10.1056.